Potential Threat of Newly Identified ST20 Clone to Enzyme Inhibitor Combination Therapy: Findings from ESCMID Global 2024

Potential Threat of Newly Identified ST20 Clone to Enzyme Inhibitor Combination Therapy: Findings from ESCMID Global 2024

2024.05.20
Carbapenem-resistant Klebsiella pneumoniae (CRKP) has emerged as a significant challenge in nosocomial infections, with its resistance escalating, drawing global attention. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Yunsong Yu's team from the Zhejiang Provincial People's Hospital presented the latest findings on the genomic epidemiology and resistance mechanisms of CRKP (Abstract No: P1673). The study indicates that ST20 CRKP carrying multiple resistance genes poses a threat to the effectiveness of novel enzyme inhibitor combination therapy, highlighting its significance in clinical anti-infective treatment and antimicrobial management strategies.
2024 CSCO Guidelines Conference | Prof. Dingwei Ye: Keeping Up with the Times, Serving Clinical Practice with a Prostate Cancer Guideline with Chinese Characteristics

2024 CSCO Guidelines Conference | Prof. Dingwei Ye: Keeping Up with the Times, Serving Clinical Practice with a Prostate Cancer Guideline with Chinese Characteristics

2024.05.20
Prostate cancer is the most common malignant tumor of the male urinary reproductive system. Compared to developed countries, China has a higher proportion of late-stage prostate cancer patients at diagnosis, resulting in poorer prognosis. In recent years, there have been rapid advancements in prostate cancer research. Therefore, developing diagnosis and treatment guidelines tailored to China based on the latest evidence-based medicine is crucial for the early diagnosis, treatment, and prognosis of Chinese prostate cancer patients. As the 2024 CSCO Guidelines Conference approaches, "Oncology Frontier" invited Prof. Dingwei Ye, Chair of the CSCO Prostate Cancer Committee and a professor at Fudan University Cancer Hospital, to discuss the guidelines.
2024 South-North Forum | Prof. Hong Hu: Should CDK4/6 Inhibitors Be Used for N0 Patients with Limited High-Risk Factors?

2024 South-North Forum | Prof. Hong Hu: Should CDK4/6 Inhibitors Be Used for N0 Patients with Limited High-Risk Factors?

2024.05.20
For hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with no lymph node involvement (N0) and limited high-risk factors, the consensus has been that their risk of recurrence is low, and adjuvant endocrine therapy alone is sufficient. However, with the release of studies like NATALEE, it has become apparent that intensifying treatment for these patients to reduce the risk of recurrence is also necessary. At the 2024 South-North Forum, Prof. Hong Hu from Shenzhen People's Hospital presented a lecture on "Adjuvant Therapy for HR+/HER2- Breast Cancer: Do N0 Patients with Limited High-Risk Factors Need CDK4/6 Inhibitors?" This article reviews the lecture content.
2024 CSCO Guidelines Conference | Prof. Jun Ma: The Chinese Society of Clinical Oncology (CSCO) Guidelines for Malignant Hematologic Diseases Promote Standardized Diagnosis and Treatment in China and Improve Clinical Outcomes

2024 CSCO Guidelines Conference | Prof. Jun Ma: The Chinese Society of Clinical Oncology (CSCO) Guidelines for Malignant Hematologic Diseases Promote Standardized Diagnosis and Treatment in China and Improve Clinical Outcomes

2024.05.20
The "2024 Chinese Society of Clinical Oncology (CSCO) Guidelines for Malignant Hematologic Diseases" are set to be released, updating the latest treatment strategies and methods for malignant hematologic diseases. This is a significant event for the hematology field in China. "Oncology Frontier" conducted an exclusive interview with Professor Jun Ma from the Harbin Institute of Hematology and Oncology to discuss the CSCO guidelines and the treatment of hematologic diseases. The interview is summarized below.
2024 EBMT Review | Professor Jun Ma:CARTITUDE-4 Study—Comparison of Efficacy between Cilta-cel and Standard Treatments in Patients with Relapsed or Refractory Multiple Myeloma

2024 EBMT Review | Professor Jun Ma:CARTITUDE-4 Study—Comparison of Efficacy between Cilta-cel and Standard Treatments in Patients with Relapsed or Refractory Multiple Myeloma

2024.05.20
From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was grandly held in Glasgow, UK, a city renowned for its historical significance. This year marks the 50th anniversary of EBMT, and the event gathered leading figures in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around the world. The attendees reviewed the remarkable achievements in the fields of hematology and bone marrow transplantation over the past 50 years and explored forward-looking patient management strategies. At the conference, chimeric antigen receptor T-cell (CAR-T) therapy, a highlight of this meeting, showcased a series of breakthroughs in the treatment of multiple myeloma and lymphoma, attracting significant attention. This issue features a special invitation to Professor Jun Ma from the Harbin Institute of Hematological Oncology to provide an insightful interpretation of five major research studies in the field of CAR-T cell therapy. Here, we present a compilation of these insights for our readers.
2024 EBMT Review | Professor Jun Ma:Development Study of Disease-Specific Composite Endpoints for CAR-T Cell Therapy in Large B-cell Lymphoma and Multiple Myeloma

2024 EBMT Review | Professor Jun Ma:Development Study of Disease-Specific Composite Endpoints for CAR-T Cell Therapy in Large B-cell Lymphoma and Multiple Myeloma

2024.05.20
From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was grandly held in Glasgow, UK, a city renowned for its historical significance. This year marks the 50th anniversary of EBMT, and the event gathered leading figures in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around the world. The attendees reviewed the remarkable achievements in the fields of hematology and bone marrow transplantation over the past 50 years and explored forward-looking patient management strategies. At the conference, chimeric antigen receptor T-cell (CAR-T) therapy, a highlight of this meeting, showcased a series of breakthroughs in the treatment of multiple myeloma and lymphoma, attracting significant attention. This issue features a special invitation to Professor Jun Ma from the Harbin Institute of Hematological Oncology to provide an insightful interpretation of five major research studies in the field of CAR-T cell therapy. Here, we present a compilation of these insights for our readers.

Guidelines Consensus | Key Insights from the “Expert Consensus on Prevention and Treatment of Chronic Hepatitis B in Children” in China

2024.05.18
With the widespread implementation of standard immunization programs and mother-to-child transmission prevention measures, the incidence of new HBV infections among children in China has significantly declined. However, due to the large base of hepatitis B patients and regional developmental disparities, the number of new and existing cases of HBV infections among children remains high.
Insights from a Study by Professor Yunsong Yu’s Team at ESCMID Global 2024

Insights from a Study by Professor Yunsong Yu’s Team at ESCMID Global 2024

2024.05.17
Carbapenem-resistant Enterobacteriaceae (CRE) has emerged as a significant global public health threat. In recent years, there has been increasing attention on ertapenem monotherapy-resistant CRE strains, making it a hot topic in the field. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study (abstract number: P1469) by Professor Yunsong Yu's team at Zhejiang Provincial People's Hospital reported on the molecular epidemiological characteristics of ertapenem monotherapy-resistant CRE. The study found that strains producing carbapenemase can still grow in high concentrations of meropenem, suggesting that monotherapy treatment may fail.
Potential Threat of Newly Identified ST20 Clone to Enzyme Inhibitor Combination Therapy: Findings from ESCMID Global 2024

Potential Threat of Newly Identified ST20 Clone to Enzyme Inhibitor Combination Therapy: Findings from ESCMID Global 2024

2024.05.17
Carbapenem-resistant Klebsiella pneumoniae (CRKP) has emerged as a significant challenge in nosocomial infections, with its resistance escalating, drawing global attention. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Yunsong Yu's team from the Affiliated Hospital of Zhejiang University School of Medicine presented the latest findings on the genomic epidemiology and resistance mechanisms of CRKP (Abstract No: P1673). The study indicates that ST20 CRKP carrying multiple resistance genes poses a threat to the effectiveness of novel enzyme inhibitor combination therapy, highlighting its significance in clinical anti-infective treatment and antimicrobial management strategies.
Professor Guosheng Ren: Highlighting the French-Chinese Breast Cancer Forum, New Technologies Lead Developments in Breast-Conserving Surgery | 2024 SFBCS

Professor Guosheng Ren: Highlighting the French-Chinese Breast Cancer Forum, New Technologies Lead Developments in Breast-Conserving Surgery | 2024 SFBCS

2024.05.17
In the vibrant spring of April in Chongqing, from April 19 to April 20, 2024, the "11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS)" was held, co-hosted by several prestigious institutions including the Chinese Anti-Cancer Association's Breast Cancer Committee, the Breast Surgery Expert Group of the Chinese Medical Doctor Association, the Oncology Clinical Research Management Committee of the Chinese Anti-Cancer Association, the Chongqing Clinical Medical Research Federation, the Breast and Thyroid Surgery Department of the First Hospital of Chongqing Medical University, the French Academy of Medical Sciences, and the French Surgical Academy Foundation. Experts from China and abroad gathered to share and exchange knowledge on basic breast cancer research, pathology diagnosis, surgical procedures, and systemic treatment, guiding new directions in the precision medicine era for breast cancer diagnosis and treatment. During the conference, "Oncology Frontier" had the privilege of interviewing Professor Guosheng Ren, the chairman of the conference, who shared insights on the highlights of the forum and the advancements in breast-conserving and reconstructive surgery.